These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8690825)

  • 21. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
    Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
    Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
    von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1994 Jul; 38(1):23-31. PubMed ID: 7946933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indications for the involvement of a CYP3A-like iso-enzyme in the metabolism of chlorobornane (Toxaphene) congeners in seals from inhibition studies with liver microsomes.
    van Hezik CM; Letcher RJ; de Geus HJ; Wester PG; Goksøyr A; Lewis WE; Boon JP
    Aquat Toxicol; 2001 Jan; 51(3):319-33. PubMed ID: 11090893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
    von Moltke LL; Durol AL; Duan SX; Greenblatt DJ
    Eur J Clin Pharmacol; 2000 Jun; 56(3):259-61. PubMed ID: 10952482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
    Martin DE; Zussman BD; Everitt DE; Benincosa LJ; Etheredge RC; Jorkasky DK
    J Clin Psychopharmacol; 1997 Dec; 17(6):451-9. PubMed ID: 9408807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.
    Greenblatt DJ; von Moltke LL; Schmider J; Harmatz JS; Shader RI
    J Clin Pharmacol; 1996 Sep; 36(9):792-8. PubMed ID: 8889899
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC; Wallace AD; Hodgson E; Rose RL
    Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.
    von Moltke LL; Greenblatt DJ; Duan SX; Schmider J; Kudchadker L; Fogelman SM; Harmatz JS; Shader RI
    Psychopharmacology (Berl); 1996 Dec; 128(4):398-407. PubMed ID: 8986010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
    Gibbs MA; Thummel KE; Shen DD; Kunze KL
    Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinician and drug interactions--an update.
    Shader RI; von Moltke LL; Schmider J; Harmatz JS; Greenblatt DJ
    J Clin Psychopharmacol; 1996 Jun; 16(3):197-201. PubMed ID: 8784649
    [No Abstract]   [Full Text] [Related]  

  • 34. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.
    Fogelman SM; Schmider J; Venkatakrishnan K; von Moltke LL; Harmatz JS; Shader RI; Greenblatt DJ
    Neuropsychopharmacology; 1999 May; 20(5):480-90. PubMed ID: 10192828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
    Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
    Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.
    Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
    J Pharmacol Exp Ther; 1995 Nov; 275(2):592-7. PubMed ID: 7473143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
    Fitzsimmons ME; Collins JM
    Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.